High biological variation of serum hyaluronic acid and hepascore, a biochemical marker model for the prediction of liver fibrosis

Clinical Chemistry and Laboratory Medicine

Volumn 51, Issue 5, 2013, Pages 1107-1114

  Rossi, Enrico ^a   Adams, Leon A ^a,b   Ching, Helena L ^a   Bulsara, Max ^c   MacQuillan, Gerry C ^a,b   Jeffrey, Gary P ^a,b  

^a PATHWEST LABORATORY MEDICINE   (Australia)

^b UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^c UNIVERSITY OF NOTRE DAME   (Australia)

Author keywords

Hepascore; Hyaluronic acid; Liver fibrosis; Reference change value; Within individual variation

Indexed keywords

ALPHA 2 MACROGLOBULIN; BILIRUBIN; BIOCHEMICAL MARKER; GAMMA GLUTAMYLTRANSFERASE; HEPASCORE; HYALURONIC ACID; UNCLASSIFIED DRUG;

ARTICLE; CHRONIC HEPATITIS; CHRONIC HEPATITIS B; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; FEMALE; HEPATITIS B; HEPATITIS C; HUMAN; LIVER FIBROSIS; MALE; NONALCOHOLIC FATTY LIVER; PREDICTION; PRIORITY JOURNAL; SERUM;

ADULT; ALPHA-MACROGLOBULINS; BIOLOGICAL MARKERS; FATTY LIVER; FEMALE; HEPATITIS B, CHRONIC; HEPATITIS C, CHRONIC; HUMANS; HYALURONIC ACID; LIVER CIRRHOSIS; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; SENSITIVITY AND SPECIFICITY; SEVERITY OF ILLNESS INDEX; YOUNG ADULT;

EID: 84882283622     PISSN: 14346621     EISSN: 14374331     Source Type: Journal    
DOI: 10.1515/cclm-2012-0584     Document Type: Article

References (37)

1. Gilmore IT, Burroughs A, Murray-Lyon IM, Williams R, Jenkins D, Hopkins A. Indications, methods, and outcomes of percutaneous liver biopsy in England and Wales: an audit by the British Society of Gastroenterology and the Royal College of Physicians of London. Gut 1995;36:437-41.
2. Ratziu V, Charlotte F, Heurtier A, Gombert S, Giral P, Bruckert E, et al. Sampling variability of liver biopsy in nonalcoholic fatty liver disease. Gastroenterology 2005;128:1898-906.
3. Adams LA. Biomarkers of liver fibrosis. Gastroenterol Hepatol 2011;26:802-9.
4. Nguyen D, Talwalkar JA. Noninvasive assessment of liver fibrosis. Hepatology 2011;53:2107-10.
5. Adams LA, Bulsara M, Rossi E, DeBoer B, Speers D, George J, et al. Hepascore: an accurate validated predictor of liver fibrosis in chronic hepatitis C infection. Clin Chem 2005;51:1867-73.
6. Raftopoulos SC, George J, Bourliere M, Rossi E, de Boer WB, Jeffrey GP, et al. Comparison of non-invasive models of fibrosis in chronic hepatitis B. Hepatol Int 2012;6:457-67 .
7. Adams LA, George J, Bugianesi E, Rossi E, De Boer WB, van der Poorten D, et al. Complex non-invasive fibrosis models are more accurate than simple models in non-alcoholic fatty liver disease. J Gastroenterol Hepatol 2011;26:1536-43.
8. Rosenberg WM, Voelker M, Thiel R, Becka M, Burt A, Schuppan D, et al. Serum markers detect the presence of liver fibrosis: A cohort study. Gastroenterology 2004;127:1704-13.
9. Vrochides D, Papanikolaou V, Pertoft H, Antoniades AA, Heldin P. Biosynthesis and degradation of hyaluronan by nonparenchymal liver cells during liver regeneration. Hepatology 1996;23:1650-5.
10. Patel K, Lajoie A, Heaton S, Pianko S, Behling CA, Bylund D, et al. Clinical use of hyaluronic acid as a predictor of fibrosis change in hepatitis C. J Gastroenterol Hepatol 2003;18:253-7.
11. Halfon P, Bourlière M, Pénaranda G, Deydier R, Renou C, Botta-Fridlund D, et al. Accuracy of hyaluronic acid level for predicting liver fibrosis stages in patients with hepatitis C virus. Comp Hepatol 2005;4:6.
12. Tran A, Hastier P, Barjoan EM, Demuth N, Pradier C, Saint-Paul MC, et al. Non invasive prediction of severe fibrosis in patients with alcoholic liver disease. Gastroenterol Clin Biol 2000;24:626-30.
13. Suzuki A, Angulo P, Lymp J, Li D, Satomura S, Lindor K. Hyaluronic acid, an accurate serum marker for severe hepatic fibrosis in patients with non-alcoholic fatty liver disease. Liver Int 2005;25:779-86.
14. Crawford DH, Murphy TL, Ramm LE, Fletcher LM, Clouston AD, Anderson GJ, et al. Serum hyaluronic acid with serum ferritin accurately predicts cirrhosis and reduces the need for liver biopsy in C282Y hemochromatosis. Hepatology 2009;49:418-25.
15. Calès P, Oberti F, Michalak S, Hubert-Fouchard I, Rousselet MC, Konat é A, et al. A novel panel of blood markers to assess the degree of liver fibrosis. Hepatology 2005;42:1373-81.
16. Patel K, Gordon SC, Jacobson I, Hézode C, Oh E, Smith KM, et al. Evaluation of a panel of non-invasive serum markers to differentiate mild from moderate-to-advanced liver fibrosis in chronic hepatitis C patients. J Hepatol 2004;41:935-42.
17. Guéchot J, Lasnier E, Sturm N, Paris A, Zarski JP; ANRS HC EP 23 Fibrostar study group. Automation of the Hepascore and validation as a biochemical index of liver fibrosis in patients with chronic hepatitis C from the ANRS HC EP 23 Fibrostar cohort. Clin Chim Acta 2010;411:86-91.
18. Fraser CG. Biological variation: from principles to practice. Washington: AACC Press, 2001:73-5.
19. Kawser CA, Iredale JP, Winwood PJ, Arthur MJ. Rat hepatic stellate cell expression of alpha2-macroglobulin is a feature of cellular activation: implications for matrix remodelling in hepatic fibrosis. Clin Sci (Lond) 1998;95:179-86.
20. Imbert-Bismut F, Ratziu V, Pieroni L, Charlotte F, Benhamou Y, Poynard T. Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: A prospective study. Lancet 2001;357:1069-75.
21. http://www.westgard.com/biodatabase1.htm#top. Accessed September, 2011.
22. Bland JM, Altman DG. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet 1986;1:307-10.
23. Bruins S, Fokkema MR, Römer JW, Dejongste MJ, van der Dijs FP, van den Ouweland JM, et al. High intraindividual variation of B-type natriuretic peptide (BNP) and amino-terminal proBNP in patients with stable chronic heart failure. Clin Chem 2004;50:2052-8.
24. Vasile VC, Saenger AK, Kroning JM, Jaffe AS. Biological and analytical variability of a novel high-sensitivity cardiac troponin T assay. Clin Chem 2010;56:1086-90.
25. Bedossa P, Poynard T. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology 1996;24:289-93.
26. Lindqvist U, Engström-Laurent A, Laurent U, Nyberg A, Björklund U, Eriksson H, et al. The diurnal variation of serum hyaluronan in health and disease. Scand J Clin Lab Invest 1988;48:765-70.
27. Rössler A, László Z, Kvas E, Hinghofer-Szalkay HG. Plasma hyaluronan concentration: no circadian rhythm but large effect of food intake in humans. Eur J Appl Physiol Occup Physiol 1998;78:573-7.
28. Hinghofer-Szalkay HG, Mekonen W, Rössler A, Schwaberger G, Lamprecht M, Hofmann P. Post-exercise decrease of plasma hyaluronan: increased clearance or diminished production? Physiol Res 2002;51:139-44.
29. Fraser JR, Laurent TC, Engström-Laurent A, Laurent UG. Elimination of hyaluronic acid from the blood stream in the human. Clin Exp Pharmacol Physiol 1984;11:17-25.
30. Idobe Y, Murawaki Y, Ikuta Y, Koda M, Kawasaki H. Post-prandial serum hyaluronan concentration in patients with chronic liver disease. Intern Med 1998;37:568-75.
31. Fraser JR, Gibson PR. Mechanisms by which food intake elevates circulating levels of hyaluronan in humans. J Intern Med 2005;258:460-6.
32. Zarski JP, Sturm N, Guechot J, Paris A, Zafrani ES, Asselah T, et al. Comparison of nine blood tests and transient elastography for liver fibrosis in chronic hepatitis C: The ANRS HCEP-23 study. J Hepatol 2012;56:55-62.
33. Friedrich-Rust M, Rosenberg W, Parkes J, Herrmann E, Zeuzem S, Sarrazin C. Comparison of ELF, FibroTest and FibroScan for the non-invasive assessment of liver fibrosis. BMC Gastroenterol 2010;10:103.
34. Frébourg T, Delpech B, Bercoff E, Senant J, Bertrand P, Deugnier Y, et al. Serum hyaluronate in liver diseases: study by enzymoimmunological assay. Hepatology 1986;6:392-5.
35. http://www.corgenixonline.com. Accessed September, 2011.
36. Wong CS, Gibson PR. Effects of eating on plasma hyaluronan in patients with cirrhosis: its mechanism and influence on clinical interpretation. J Gastroenterol Hepatol 1998;13: 1218-24.
37. Majeed M, McQueen F, Yeoman S, McLean L. Relationship between serum hyaluronic acid level and disease activity in early rheumatoid arthritis. Ann Rheum Dis 2004;63:1166-8.